Skip to main content

Advertisement

Log in

Clinical outcomes of uterine arterial chemoembolization with drug-eluting beads for advanced-stage or recurrent cervical cancer

  • Interventional Radiology
  • Published:
Abdominal Radiology Aims and scope

Abstract

Purpose

To study the clinical efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) among women with advanced-stage or recurrent cervical cancer.

Methods

This retrospective cohort study enrolled women with cervical cancer who were treated by DEB-TACE between April 3, 2017 and July 12, 2021. Inclusion criteria were pathologic diagnosis of cervical cancer, II–IVa period, being aged 18 to 80 years, patient's inclination of treatment with DEB-TACE, and complete clinicopathologic data. Direct medical cost, hospital stay, resection frequency, treatment responses, adverse events, overall survival, and progression-free survival were investigated.

Results

A total of 16 women with cervical cancer were treated by DEB-TACE. DEB-TACE was successfully performed in all patients, with no major complications or adverse events. A total of 10 minor complications were observed in 9 women (56.3%) after the procedure. Seven (43.8%) women experienced mild to moderate post-embolization pain. The tumors decreased 3 and 6 months after the treatment. The frequency of complete response, partial response, stable disease, and progressive disease was 1 (40%), 3 (40%), 12 (15%), and 0 (0%), respectively, resulting in an objective response rate of 25.0% and a disease control rate of 100.0% after 1 month. The median hospital stay was 9.5 days, and the direct medical cost was 5.9 × 104 ¥. The median follow-up time was 4.1 months (interquartile range 2.6–23.7 months). The median overall survival was 19.1 months, and the 1- and 3-year survival rate was 64.9% and 46.4%, respectively.

Conclusion

DEB-TACE with diamminedichloroplatinum-preloaded beads may be an effective and safe treatment for women with advanced-stage or recurrent cervical cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

For further details, the corresponding author can be contacted.

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 2015, 65:87-108.

    Article  Google Scholar 

  2. Waggoner SE (2003) Cervical cancer. Lancet 2003, 361:2217-2225.

    Article  Google Scholar 

  3. Peters WA, 3rd, Liu PY, Barrett RJ, 2nd et al (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000, 18:1606-1613.

    Article  CAS  Google Scholar 

  4. Tian ZZ, Li S, Wang Y, Yue YJ, Zhu XH, Zhao R, Zhang CL, Wei SH (2014) Investigation of uterine arterial chemoembolization and uterine arterial infusion chemotherapy for advanced cervical cancer before radical radiotherapy: a long-term follow-up study. Arch Gynecol Obstet 2014, 290:155-162.

    Article  CAS  Google Scholar 

  5. Cucchetti A, Trevisani F, Cappelli A, Mosconi C, Renzulli M, Pinna AD, Golfieri R (2016) Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. Dig Liver Dis 2016, 48:798-805.

    Article  Google Scholar 

  6. Bi Y, Shi X, Ren J, Yi M, Han X, Song M (2021) Transarterial chemoembolization with doxorubicin-loaded beads for inoperable or recurrent colorectal cancer. Abdom Radiol (NY) 2021.

    Article  Google Scholar 

  7. Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007, 46:474-481.

    Article  CAS  Google Scholar 

  8. Huang K, Zhou Q, Wang R, Cheng D, Ma Y (2014) Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2014, 29:920-925.

    Article  CAS  Google Scholar 

  9. Bi Y, Shi X, Ren J, Yi M, Han X, Song M (2021) Clinical outcomes of doxorubicin-eluting CalliSpheres(R) beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma. BMC Gastroenterol 2021, 21:231.

    Article  CAS  Google Scholar 

  10. Song J, Chen W, Zhu X et al (2019) Short-term efficacy, safety, and cost-effectiveness of transarterial chemoembolization with drug-eluting beads versus synchronous radiochemotherapy for cervical cancer. Int J Gynaecol Obstet 2019, 147:29-35.

    Article  CAS  Google Scholar 

  11. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010, 30:52-60.

    Article  CAS  Google Scholar 

  12. Yu L, Tan GS, Xiang XH, Guo WB, Li HP, Huang YH, Yang JY (2009) [Comparison of uterine artery chemoembolization and internal iliac arterial infusion chemotherapy for the combining treatment for women with locally advanced cervical cancer]. Ai Zheng 2009, 28:402-407.

    PubMed  Google Scholar 

  13. Kapp KS, Poschauko J, Tauss J, Berghold A, Oechs A, Lahousen M, Petru E, Winter R, Kapp DS (2005) Analysis of the prognostic impact of tumor embolization before definitive radiotherapy for cervical carcinoma. Int J Radiat Oncol Biol Phys 2005, 62:1399-1404.

    Article  Google Scholar 

  14. Sukhaboon J, Porapakkhan P, Penpattanagul S (2009) Randomized comparison of fluorouracil plus cisplatin vs. cisplatin as an adjunct to radiation therapy in stage IIB-IVA squamous cell carcinoma of the cervix: pilot study. J Med Assoc Thai 2009, 92:1072-1076.

    PubMed  Google Scholar 

  15. Hodge LS, Downs LS, Jr., Chura JC, Thomas SG, Callery PS, Soisson AP, Kramer P, Wolfe SS, Tracy TS (2012) Localized delivery of chemotherapy to the cervix for radiosensitization. Gynecol Oncol 2012, 127:121-125.

    Article  CAS  Google Scholar 

  16. Bi Y, Shi X, Yi M, Han X, Ren J (2021) Pirarubicin-loaded CalliSpheres(R) drug-eluting beads for the treatment of patients with stage III-IV lung cancer. Acta Radiol 2021:284185121994298.

    Google Scholar 

  17. Favero G, Pierobon J, Genta ML et al (2014) Laparoscopic extrafascial hysterectomy (completion surgery) after primary chemoradiation in patients with locally advanced cervical cancer: technical aspects and operative outcomes. Int J Gynecol Cancer 2014, 24:608-614.

    Article  Google Scholar 

  18. Kozaki M, Sakuma S, Kudaka W et al (2017) Therapy-free interval has prognostic value in patients with recurrent cervical cancer treated with chemotherapy following definitive concurrent chemoradiotherapy. Arch Gynecol Obstet 2017, 296:997-1003.

    Article  Google Scholar 

  19. Chen YF, Tang WB, Pan XX, Wu CR, Cao Y, Yang W (2017) Safety and efficacy of nimotuzumab combined with chemoradiotherapy in Chinese patients with locally advanced cervical cancer. Onco Targets Ther 2017, 10:4113-4119.

    Article  Google Scholar 

  20. Haraga J, Nakamura K, Omichi C et al (2016) Pretreatment prognostic nutritional index is a significant predictor of prognosis in patients with cervical cancer treated with concurrent chemoradiotherapy. Mol Clin Oncol 2016, 5:567-574.

    Article  CAS  Google Scholar 

  21. Mitchell PA, Waggoner S, Rotmensch J, Mundt AJ (1998) Cervical cancer in the elderly treated with radiation therapy. Gynecol Oncol 1998, 71:291-298.

    Article  CAS  Google Scholar 

  22. Kobayashi K, Furukawa A, Takahashi M, Murata K (2003) Neoadjuvant intra-arterial chemotherapy for locally advanced uterine cervical cancer: clinical efficacy and factors influencing response. Cardiovasc Intervent Radiol 2003, 26:234-241.

    Article  Google Scholar 

  23. Lorvidhaya V, Chitapanarux I, Sangruchi S, Lertsanguansinchai P, Kongthanarat Y, Tangkaratt S, Visetsiri E (2003) Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys 2003, 55:1226-1232.

    Article  CAS  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

Authors

Contributions

Concept and design: XH and JR; data collection: YB, XS, YW, and MX; manuscript drafting: YB, YW, and JZ; statistical analysis: YB and YW; administrative support: XH and JR. All authors discussed the results and revised the manuscript.

Corresponding authors

Correspondence to Xinwei Han or Jianzhuang Ren.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was approved by the Ethics Committee of The First Affiliated Hospital of Zhengzhou University.

Consent to participate

Written informed consent was waived due to its retrospective nature.

Consent for publication

Written informed consents were obtained from the patients for publication. A copy of the written consent is available for review by the Editor of this journal.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bi, Y., Wang, Y., Zhang, J. et al. Clinical outcomes of uterine arterial chemoembolization with drug-eluting beads for advanced-stage or recurrent cervical cancer. Abdom Radiol 46, 5715–5722 (2021). https://doi.org/10.1007/s00261-021-03267-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-021-03267-6

Keywords

Navigation